![conference banner](/images/conference-banner.jpeg)
Abstract
The use of highly active antiretroviral therapy (HAART) has significantly slowed the HIV disease progression. However, adverse effects are now a limiting cause of HAART benefit in a substantial proportion of patients. Particularly hepatotoxicity which is a common complication occurring during every HAART regimen. All antiretroviral (ARV) drugs classes, Nucleoside/Nucleotide reverse transcriptase inhibitors (NRTI), non-Nucleoside reverse transcriptase inhibitors (nNRTI) and Protease Inhibitors (PI) may cause hepatotoxicity but in different pathways. Many risk factors have been identified for developing antiretroviral-related hepatotoxicity, however severe hepatitis remains very uncommon in patients receiving HAART, also if the incidence of hepatotoxicity is rather high. That being the case, means that every new available antiretroviral drug strongly necessities studies which can evaluate its hepatotoxicity and drug-drug interactions, to define the potential risk factors and the outcome of any side effects. This report will review the risk factors, the epidemiology and the pathogenic mechanisms of hepatotoxicity caused in every antiretroviral drug.
Keywords: aids, hiv, haart, antiretroviral drugs, haart hepatotoxicity, antiretroviral drugs hepatotoxicity, management of haart hepatotoxicity, management of antiretroviral drugs hepatotoxicity
Current Pharmaceutical Design
Title: Hepatotoxicity of Antiretroviral Drugs
Volume: 11 Issue: 28
Author(s): N. Abrescia, M. D'Abbraccio, M. Figoni, A. Busto, A. Maddaloni and M. D. Marco
Affiliation:
Keywords: aids, hiv, haart, antiretroviral drugs, haart hepatotoxicity, antiretroviral drugs hepatotoxicity, management of haart hepatotoxicity, management of antiretroviral drugs hepatotoxicity
Abstract: The use of highly active antiretroviral therapy (HAART) has significantly slowed the HIV disease progression. However, adverse effects are now a limiting cause of HAART benefit in a substantial proportion of patients. Particularly hepatotoxicity which is a common complication occurring during every HAART regimen. All antiretroviral (ARV) drugs classes, Nucleoside/Nucleotide reverse transcriptase inhibitors (NRTI), non-Nucleoside reverse transcriptase inhibitors (nNRTI) and Protease Inhibitors (PI) may cause hepatotoxicity but in different pathways. Many risk factors have been identified for developing antiretroviral-related hepatotoxicity, however severe hepatitis remains very uncommon in patients receiving HAART, also if the incidence of hepatotoxicity is rather high. That being the case, means that every new available antiretroviral drug strongly necessities studies which can evaluate its hepatotoxicity and drug-drug interactions, to define the potential risk factors and the outcome of any side effects. This report will review the risk factors, the epidemiology and the pathogenic mechanisms of hepatotoxicity caused in every antiretroviral drug.
Export Options
About this article
Cite this article as:
Abrescia N., D'Abbraccio M., Figoni M., Busto A., Maddaloni A. and Marco D. M., Hepatotoxicity of Antiretroviral Drugs, Current Pharmaceutical Design 2005; 11 (28) . https://dx.doi.org/10.2174/138161205774580804
DOI https://dx.doi.org/10.2174/138161205774580804 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Advanced Therapies For End-Stage Heart Failure
Current Cardiology Reviews Nitric Oxide in Atherosclerosis
Mini-Reviews in Medicinal Chemistry Fetal Undernutrition and the Programming of Blood Pressure
Current Nutrition & Food Science Natural Compounds A Weapon to Ameliorate Breast Cancer Cells: A Review
Anti-Cancer Agents in Medicinal Chemistry Role of Conventional and Novel Classes of Diuretics in Various Diseases
Current Drug Therapy Antihypertensive Effects of SGLT2-Inhibitors: Considerations for Clinical Practice
Current Vascular Pharmacology New Highly Potent and Selective Adenosine A3 Receptor Antagonists
Current Topics in Medicinal Chemistry Losartan Chemistry and Its Effects via AT1 Mechanisms in the Kidney
Current Medicinal Chemistry Potential Therapeutic Interest of Adenosine A2A Receptors in Psychiatric Disorders
Current Pharmaceutical Design Targeting B Cells in SLE: The Experience with Rituximab Treatment (Anti-CD20)
Endocrine, Metabolic & Immune Disorders - Drug Targets Scope and Limitations of The Co-Drug Approach to Topical Drug Delivery
Current Pharmaceutical Design Pathogenesis of Acute Kidney Injury During Sepsis
Current Drug Targets Antioxidant and Antiangiogenic Effect of Homoleptic Palladium (II) Carboxamide Complex Loaded Chitosan Modified PLGA Nanoparticles: <i>In vitro</i> Evaluation and <i>In vivo</i> Chick Embryo Chorioallantoic Membrane (CAM) Assay
Letters in Drug Design & Discovery Chiral Kinase Inhibitors
Current Topics in Medicinal Chemistry Effects of Amine Oxidases in Allergic and Histamine-Mediated Conditions
Recent Patents on Inflammation & Allergy Drug Discovery Prolonged Exposure to Ketamine Increases Brain Derived Neurotrophic Factor Levels in Developing Rat Brains
Current Drug Safety Functional Neuroanatomy of the Noradrenergic Locus Coeruleus: Its Roles in the Regulation of Arousal and Autonomic Function Part I: Principles of Functional Organisation
Current Neuropharmacology Effects of Physical Exercise on Depressive Symptoms and Biomarkers in Depression
CNS & Neurological Disorders - Drug Targets Levosimendan: A Novel Agent in Heart Failure
Recent Patents on Cardiovascular Drug Discovery Angiotensin Converting Enzyme Inhibitor in Coronary Artery Bypass Surgery
Drug Design Reviews - Online (Discontinued)